Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831127 | 0.90 | NPC1 (0.66) | L3MBTL1NPC1MEN1POLBKMT2A | |
| SCHEMBL8975652 | 0.86 | HPGD (0.57) | L3MBTL1NPC1MEN1KMT2ATP53 | |
| SCHEMBL29265630 | 0.85 | NPC1 (0.49) | L3MBTL1NPC1MEN1POLBKMT2A | |
| SCHEMBL11146761 | 0.85 | HCAR3 (0.58) | L3MBTL1NPC1MEN1POLBKMT2A | |
| SCHEMBL21082729 | 0.84 | L3MBTL1 (0.66) | L3MBTL1NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL16016477 | 0.83 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14207379 | 0.81 | MEN1 (0.46) | L3MBTL1NPC1MEN1POLBKMT2A | |
| SCHEMBL9458908 | 0.81 | MAPT (0.54) | NPC1MEN1POLBKMT2ATP53 | |
| SCHEMBL10154271 | 0.80 | L3MBTL1 (0.50) | L3MBTL1TSHRSMN1; SMN2CA2CA12 | |
| SCHEMBL29114273 | 0.80 | PTGES (0.51) | MEN1KMT2ATP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| EP-2488486-B1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARM INC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3184448-B1 | MULTILAYER PLASTIC CONTAINER | MITSUBISHI GAS CHEMICAL CO (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| CN-107709315-A | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2018-02-16 | — | — | CN | disclosed |
| US-20170267436-A1 | MULTILAYER PLASTIC CONTAINER | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2017-09-21 | — | — | US | disclosed |
| EP-3184448-A1 | MULTILAYER PLASTIC CONTAINER | Mitsubishi Gas Chemical Company, Inc. (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-1976932-A | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0778209-B1 | Oxygen absorbing container | TOYO SEIKAN KAISHA LTD (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5800887-A | CARBON MONOXIDE-STYRENE OR ETHYLENE COPOLYMER | TOYO SEIKAN KAISHA, LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0778209-A1 | Oxygen absorbing container | TOYO SEIKAN KAISHA LIMITED (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-RE35135-E | Dental material; mixture of radical-polymerizable monomer, alpha-ketocarbonyl and aromatic amine | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0136186-B1 | PHOTOCURABLE RESIN COMPOSITION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4548689-A | RADICAL POLYMERIZABLE MONOMER, KETOCARBONYL COMPOUND AND MERCAPTOB | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | L3MBTL1 1168/4885NPC1 4275/4885MEN1 3653/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | L3MBTL1 2709/4885NPC1 2042/4885MEN1 1457/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | L3MBTL1 1168/4885NPC1 4275/4885MEN1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.